Access to genetic testing for IRDs
Inherited retinal diseases (IRDs, also known as inherited retinal dystrophies) are a group of rare blinding conditions caused by one of more than 220 different genes. It is estimated that more than two million people live with inherited retinal diseases (IRDs) globally, but only a small percentage of them have been genetically screened because of limited access to and information about genetic testing. In response to feedback from advocates, families affected by IRDs and healthcare professionals about the current barriers preventing access to genetic screening for IRDs in a consistent manner, Spark Therapeutics has been working closely with physicians in the U.S., South America and Europe to help facilitate access to genetic screening for people with IRDs.
For more information about a treatment for appropriate patients with a specific IRD, click here.
Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Progress in Retinal and Eye Research. 2010;29(5):335-375.
Sahel J-A, Marazova K, Audo I. Clinical Characteristics and Current Therapies for Inherited Retinal Degenerations. Cold Spring Harbor Perspectives in Medicine. 2014;5(2).
Veleri S, Lazar CH, Chang B, Sieving PA, Banin E, Swaroop A. Biology and therapy of inherited retinal degenerative disease: insights from mouse models. Dis Model Mech Disease Models & Mechanisms. 2015;8(2):109-129.